BridgeBio Pharma (BBIO) Cash from Operations (2018 - 2026)

BridgeBio Pharma (BBIO) has 9 years of Cash from Operations data on file, last reported at 197279000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations rose 0.98% year-over-year to 197279000.0; the trailing twelve-month figure through Mar 2026 stood at 443954000.0 (up 11.28% YoY), and the FY2025 full-year result was 445910000.0, up 14.37% from the prior year.
• Cash from Operations eased to 197279000.0 in Q1 2026, from 56420000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 74703000.0 in Q2 2024 to a low of 219537000.0 in Q1 2024.
• A 5-year average of 124184058.82 and a median of 135163000.0 in 2022 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations slumped 272.22% in 2023 and jumped 165.9% in 2024, its largest moves.
• Tracing BBIO's Cash from Operations over 5 years: stood at 93243000.0 in 2022, then tumbled by 33.86% to 124819000.0 in 2023, then sank by 56.49% to 195326000.0 in 2024, then soared by 71.11% to 56420000.0 in 2025, then plunged by 249.66% to 197279000.0 in 2026.
• Business Quant data shows BBIO's Cash from Operations at 197279000.0 in Q1 2026, 56420000.0 in Q4 2025, and 109574000.0 in Q3 2025.